EUFOREA/EPOS共识:慢性鼻窦炎伴鼻息肉的手术与生物制剂治疗
该共识由EUFOREA/EPOS国际多学科专家组制定,通过综述关键RCT、真实世界研究及指南并经多轮讨论投票形成。共识明确了ESS与生物制剂在CRSwNP中的目标、适应证、时机及治疗定位,强调弥漫性病变患者至少应完成一次完整ESS,不推荐同时启动手术与生物治疗,并重申既往指南的生物制剂适应证。
要点
- 弥漫性病变患者应至少完成一次完整ESS。
- 当前证据不推荐同时启动鼻窦手术与生物制剂治疗。
- 生物制剂适应证沿用既往指南,长期全身糖皮质激素不再被接受。
核心结论
- 共识为CRSwNP中ESS与生物制剂的个体化、循证治疗提供统一框架。
- 弥漫性病变患者应至少接受一次完整ESS。
- 当前证据不支持同时启动鼻窦手术与生物制剂治疗。
- 生物制剂适应证沿用既往指南,长期全身糖皮质激素不再被接受。
研究设计与样本
- EUFOREA/EPOS国际多学科专家组达成共识。
- 证据来源包括关键RCT、真实世界研究及近期指南。
- 共识声明经多轮讨论和投票起草与修订。
主要发现
- ESS与生物制剂均已被证实有效,但最佳顺序、范围及时机仍存争议。
- 专家组就ESS与生物制剂的目标、适应证、时机及治疗定位达成共识。
- 强调新型治疗策略的互补与疾病修饰作用。
关键数值与推荐
- 弥漫性病变患者应至少完成一次完整ESS。
- 当前证据下不推荐同时启动鼻窦手术与生物制剂治疗。
- 生物制剂治疗适应证沿用既往指南。
- 长期全身糖皮质激素不再被接受,尤其在有生物制剂可用时。
临床怎么用
- 对弥漫性CRSwNP患者应优先完成至少一次完整ESS。
- 避免同时启动鼻窦手术与生物制剂治疗。
- 生物制剂使用应遵循既往指南适应证。
- 避免长期全身糖皮质激素治疗,优先考虑生物制剂。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The therapeutic landscape of chronic rhinosinusitis with nasal polyps (CRSwNP) has rapidly evolved over the past 6 years with the arrival of biologics, prompting a re-evaluation of the traditional stepwise management centred on corticosteroids and endoscopic sinus surgery (ESS). Although both ESS and biologics have proven efficacy, the optimal sequence, extent and timing of ESS relative to biologics remains a matter of debate. The international multidisciplinary panel of experts of EUFOREA/EPOS reached consensus on the aims, indications, timing, and therapeutic positioning of ESS, and biologics in CRSwNP. Evidence from pivotal RCTs, real-life studies and recent guidelines was critically reviewed. Consensus statements were drafted and refined through multiple rounds of discussion and voting. This EUFOREA/EPOS report provides key definitions and clinical criteria for ESS and biologics particiin CRSwNP, offering a unified framework for personalized, evidence-based care with the aim to achieve the best outcomes for patients. The expert group agreed that patients with diffuse disease should have at least a primary complete ESS, that concurrent initiation of sinus surgery and biologic therapy is not recommended with current evidence, and the indication for biologic therapy as established by earlier guidelines were enforced. It was emphasized that with the current knowledge on side effects of systemic corticosteroids, their long-term use is no longer accepted especially where biologics are available. By emphasizing complementary and disease-modifying effects of novel care strategies, this initiative aims at optimizing outcomes across the entire airway continuum in line with EPOS/EUFOREA's mission.
引用
- de Corso E, Hellings PW, Fokkens WJ, et al. Surgery and/or biologics in chronic rhinosinusitis with nasal polyps: EUFOREA/EPOS consensus paper. Rhinology. 2026. PMID: 42858259. doi:10.4193/Rhin26.064
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。